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• Atrial fibrillation (AF) is the most prevalent arrythmia 
diagnosed in the US. Among patients with AF there is a 5 times 
increased risk of stroke. Current stroke preventions regimens 
related to AF include oral anticoagulants such as Warfarin or 
more recently introduced factor II/Xa inhibitors5,3.
• The PROTECT AF and PREVAIL trials showed the benefits of 
WATCHMAN device as an alternate therapy in patients with AF 
and contraindications to current stroke regimens for 
cardioembolic stroke prevention2. 
• One of the major complications with WATCHMAN left atrial 
appendage closure (LAAC) is device related thrombus (DRT). 
Currently there are no published recommendations on 
management of DRT post-LAA closure using WATCHMAN 
device6. 
• We report the management of a patient with AF and GI bleed 
who underwent left atrial appendage occlusion using 
WATCHMAN complicated by device related thrombus. 
• A 77-year-old female with paroxysmal AF was referred to our 
institution for LAAC. CHA2DS2-VASc and HASBLED scores 
were 4. 
• Appropriately treated with coumadin but was switched to 
dabigatran secondary to labile INR. 
• Management complicated by gastro-intestinal (GI) bleed →
referred for LAAC evaluation. 
• A trans-esophageal echocardiogram (TEE) found the 
appendage anatomy suitable for LAAC 
• Successfully underwent a 33 mm WATCHMAN implant and 
was discharged on full dose dabigatran along with aspirin.
• However, patient’s cardiologist had reduced it to half dose 
dabigatran due to concern for GI bleed. Additionally, the 
patient stopped taking aspirin. 
• At a 45 day follow up TEE demonstrated a device associated 
thrombus measuring 3.6 cm x 2.2 cm covering the entire 
WATCHMAN device surface facing the left atrium. No 
significant flow around the device noted. 
• She was admitted and started on intravenous (IV) heparin 
infusion. 
• After consulting with cardiothoracic surgery to consider 
surgical removal of the thrombus, decision was made to treat 
her conservatively using IV heparin followed by Coumadin with 
repeat TEE few weeks later to re-assess the thrombus burden.
• A follow up TEE a month later showed a significant reduction in 
size of the thrombus.
• She was continued on warfarin which was well tolerated and a 
TEE was repeated 2 months later that showed resolution of the 
thrombus. 
• Typically, LAAC devices require a short-term course of OAC for 
a few weeks to months during device endothelization but in 
some patients complete endothelization may not occur which 
can increase the risk of peri-device leak and device related 
thrombus6. 
• The recommended post implant management by PROTECT AF 
trail includes aspirin and warfarin to achieve INR of 2-4 until 
45-day visit.
• Risk factors associated with DRT have been examined by very 
few studies which include: left ventricular ejection fraction of 
<40%, pre existing LAA thrombus, LAA peak emptying velocity, 
smoking and a higher CHA2DS2-VASc score4. 
• A multicenter study with 214 patients proved NOACs to be a 
feasible alternate regimen to warfarin to prevent DRT and 
thromboembolic complications post LAAC1.
• In this report, dabigatran, a NOAC was used post procedurally 
to prevent device associated thrombus but given the patients 
risk factors of high CHADS-VASc score we believe that the 
continued half dose was possibly inadequate for DRT 
prevention. Additionally the patient was also not taking 
aspirin during the critical first few week's post device implant. 
• After the failed approach with dabigatran and aspirin, and in 
favor of a more conservative approach to avoid LAA 
amputation, we opted for inpatient IV heparin and continued 
warfarin for 1 year which led to resolution of the thrombus.
• Further research needs to go into the duration and choice of 
anticoagulation for management of device related thrombus.
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Figure 2: Resolution of device associated thrombus 
post conservative treatment. Watchman device (red 
arrow)
Figure 1: Device associated thrombus (red arrow) 
